lundi 3 décembre 2018

Onco Actu du 3 décembre 2018 - Spécial ASH


5.8 ASH

ASH Highlights for Sunday, December 2, 2018 [OBR]

ASH18: Cancer drug trials in need of modernization, NCI director says [BiopharmaDive]

5.8.1 ASH - Communiqués

Major Trials Show Benefits of New Therapy Regimens for Cancer and Blood Disorders [ASH]

5.8.2 ASH - Pharma

ASH18: Trial successes back Celgene belief in luspatercept [BiopharmaDive]

Celgene Corporation and Acceleron Pharma Announce Results of the Phase 3 MEDALIST Trial Evaluating Luspatercept in Patients with Myelodysplastic Syndromes at the ASH 2018 Plenary Session [Celgene]

5.8.4 ASH - CAR T

ASH18: Bluebird's follow-on CAR-T finds initial success, but durability will be key test [BiopharmaDive]

Kite Announces Two-Year Data for Yescarta® (Axicabtagene Ciloleucel) in Patients With Refractory Large B-Cell Lymphoma [Gilead]

ASH18: CAR-T shows up in early CLL test [BiopharmaDive]

ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah [FiercePharma]

Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers [Novartis]

bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting [bluebirdbio]

ASH 2018: A first stem cell transplant after CAR T-Cell therapy reduces relapses in ALL [ecancer News]

#ASH18: Gilead posts impressive survival rates for Yescarta — but sales remain lean [EndPoints]

#ASH18: Bluebird and Celgene didn’t ‘break’ their next-gen BCMA CAR-T, so now they’ll double down on the dose and root for real durability [EndPoints]

#ASH18: Celgene offers up a stellar complete response rate for JCAR017. Will anyone notice? [EndPoints]

CAR T-Cell Therapies Show Durable Responses, New Research Also Explores Combination Therapies to Extend and Enhance Treatment Responses [ASH]

More than half of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma in ZUMA-1 trial [MD Anderson Cancer Center]

High-cost Gilead cell therapy proves durable for some lymphoma patients [Reuters]

5.8.5 ASH - Myélome multiple

ASH: Takeda maintenance data sets up Ninlaro for new myeloma nod [FiercePharma]

Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting [Takeda]

DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma [Johnson&Johnson]

5.8.6 ASH - Leucémies

Celgene Corporation Announces Initial Phase 1/2 Liso-cel Data in Patients with Relapsed/Refractory CLL, Including Those with High-Risk Disease, Previously Treated with Ibrutinib, at ASH 2018 [Celgene]

AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course [AbbVie]

IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton's Tyrosine Kinase Inhibitor to Date [AbbVie]

Tolero Pharmaceuticals Presents Updated Clinical Data from Ongoing Phase 2 Zella 201 Study Evaluating Investigational Agent Alvocidib in Patients with MCL-1 Dependent Relapsed or Refractory AML at ASH 2018 [Tolero]

ASH 2018: Rapid genetic screening shows feasibility of precision medicine for acute myeloid leukaemia [ecancer News]

5.8.7 ASH - Lymphomes

Seattle Genetics Highlights Multiple Data Sets Evaluating the Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) at ASH Annual Meeting [Seattle Genetics]

Seattle Genetics Highlights Additional Analyses from ECHELON-1 Phase 3 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Newly Diagnosed Advanced Hodgkin Lymphoma at ASH Annual Meeting [Seattle Genetics]

Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting [Pfizer]

Celgene Corporation Announces Results of AUGMENT Evaluating REVLIMID® In Combination with Rituximab (R²) In Patients with Relapsed/Refractory Indolent Lymphoma At ASH 2018 [Celgene]

#ASH18: Regeneron’s bispecific REGN1979 offers eye-catching 80% CR rate in follicular lymphoma, spurring swift shift to pivotal study [EndPoints]